Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Azacitidine 4pirtobrutinib 3Cyclophosphamide 3venetoclax 2ibrutinib 2fludarabine 2Mycophenolic Acid 2Lenalidomide 2zanubrutinib 1ruxolitinib 1ponatinib 1nilotinib 1idelalisib 1idecabtagene vicleucel 1fludarabine phosphate 1cedazuridine 1cc-486 1asciminib 1acalabrutinib 1Whole-Body Irradiation 1Vancomycin 1Tretinoin 1Tacrolimus 1Sirolimus 1Semen Analysis 1Rituximab 1Quality of Life 1Physical Examination 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × cc-486 × 90 days × Clear all
NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Celgene

Phase 2 Completed
5 enrolled 10 charts
Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡